The Technical Analyst
4D Molecular [FDMT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
4D Molecular Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.06% $24.78
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 267.68 mill |
| EPS: | -2.58 |
| P/E: | -9.60 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 51.16 mill |
| Avg Daily Volume: | 1.233 mill |
| RATING 2024-04-18 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.60 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.63x |
| Company: PE -9.60 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-9.89 (-139.93%) $-34.67 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 22.70 - 26.86 ( +/- 8.41%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-16 | Bizily Scott | Sell | 1 250 | Stock Option (Right To Buy) |
| 2024-04-16 | Bizily Scott | Sell | 500 | Stock Option (Right To Buy) |
| 2024-04-16 | Bizily Scott | Buy | 1 250 | Common Stock |
| 2024-04-16 | Bizily Scott | Buy | 500 | Common Stock |
| 2024-04-16 | Bizily Scott | Sell | 1 750 | Common Stock |
| INSIDER POWER |
|---|
| 31.11 |
| Last 99 transactions |
| Buy: 3 571 023 | Sell: 1 811 773 |
Forecast:
16:00 - $24.76
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $24.76
Forecast 2: 16:00 - $24.76
Forecast 3: 16:00 - $24.76
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $24.78 (-2.06% ) |
| Volume | 0.406 mill |
| Avg. Vol. | 1.233 mill |
| % of Avg. Vol | 32.93 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FDMT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $26.80 | N/A | Active |
|---|
FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-28 08:00:00 - Press Release
4dmt Announces Update On Regulatory Interactions And Development Path For 4d-710 For Treatment Of Cystic Fibrosis
Emeryville, calif., march 28, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced an update on its regulatory interactions and development path for 4d-710, an aerosolized genetic medicine for the treatment of cf lung disease.
2024-03-04 08:00:00 - Press Release
4dmt To Participate In Upcoming Investor Conferences
Emeryville, calif., march 04, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in march. members of the management team will also be available for one-on-one meetings.
2024-02-29 16:05:00 - Press Release
4dmt Reports Full Year 2023 Financial Results And Operational Highlights
Emeryville, calif., feb. 29, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported full year 2023 financial results and provided operational highlights.
2024-02-12 08:00:00 - Press Release
4dmt Presents Interim Data From 4d-310 Inglaxa Phase 1/2 Clinical Trials For Fabry Disease Cardiomyopathy At Worldsymposium™ 2024
Emeryville, calif., feb. 12, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced updated interim safety and efficacy data on six adults with fabry disease cardiomyopathy treated with a single intravenous (iv) infusion of 4d-310 (1e13 vg/kg) with follow-up of 12-33 months overall, including 12-24 month follow-up data on cardiac contractility, exercise capacity, quality of life and cardiac biopsy data. the data was presented in a late-breaking session at worldsymposium™ 2024 in san diego, california on friday, february 9, 2024.
2024-02-06 23:27:00 - Press Release
4d Molecular Therapeutics Announces Pricing Of Upsized Public Offering Of Common Stock
Emeryville, calif., feb. 06, 2024 (globe newswire) -- 4d molecular therapeutics, inc. (nasdaq: fdmt), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it priced an upsized underwritten public offering of 6,586,015 shares of its common stock at a public offering price of $29.50 per share and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 3,583,476 shares of common stock at a public offering price of $29.4999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant...
Latest News
2024-03-04 08:00:00 - GlobeNewsWire
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.
2024-02-29 19:06:18 - Zacks Investment Research
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago.
2024-02-05 14:50:31 - InvestorPlace
Why Is 4D Molecular (FDMT) Stock Up 85% Today?
Some massive winners in the world of biotech companies continue to emerge today. 4D Molecular Therapeutics (NASDAQ: FDMT ) is the latest company to generate massive attention from investors, with FDMT stock rocketing over 80% higher in early afternoon trading.
2024-02-05 12:41:38 - Reuters
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy.
2024-01-29 08:00:00 - GlobeNewsWire
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
EMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that it will host a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden, as well as provide a program update on Monday, February 5 at 8:00 a.m. ET. Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, will also present in the webcast and be available for Q&A.
2024-01-19 13:01:05 - Zacks Investment Research
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
4D Molecular Therapeutics, Inc. (FDMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-12-04 08:00:00 - GlobeNewsWire
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that the initial interim landmark data analysis (24 weeks) from the randomized Dose Expansion stage (N=50) of the Phase 2 PRISM clinical trial in high anti-VEGF (vascular endothelial growth factor) treatment need (6-12 anti-VEGF injections in prior 12 months) wet AMD patients will be presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference being held virtually on February 3, 2024.
2023-11-15 08:00:00 - GlobeNewsWire
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, announced today that management will participate in a fireside chat at an upcoming investor conference in November. Members of the management team will also be available for one-on-one meetings in connection with this meeting.
2023-10-25 08:00:00 - GlobeNewsWire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET.
2023-09-25 12:19:17 - Seeking Alpha
4D Molecular Therapeutics: Some Failures, A Few Key Successes
4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions in patients. The company has five product candidates in clinical trials, targeting ophthalmology, cardiology, and pulmonology. The cystic fibrosis program with 4D-710 showed success, with improvements in lung function and quality of life, providing a potential breathing space for patients ineligible for other treatments.